Fortis Healthcare Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare's Board, at its meeting on August 6, 2025, approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations rose to Rs 43,303 lacs from Rs 33,340 lacs in Q1 FY25, a growth of about 30% year-on-year. Total income stood at Rs 47,304 lacs versus Rs 36,883 lacs. Net profit jumped to Rs 5,188 lacs from Rs 2,683 lacs, helped by a Rs 1,688 lacs exceptional gain from reversal of impairment in subsidiary investments. EBITDA rose to Rs 12,812 lacs from Rs 9,337 lacs, while EPS came in at Rs 0.69 versus Rs 0.36. The Board also appointed M/s. B S R & Co. LLP as Tax Auditors for FY 2024-25.
Strong Q1 results with sharp YoY growth in revenue and profit, along with continued improvement in operating margins, are positive for shareholders. Ongoing legal matters (SFIO investigation, Fortis/SRL brand-related cases) remain overhangs but no new financial impact was identified in this quarter.